Catalent Stock Forecast for 2023 - 2025 - 2030

Updated on 02/05/2023

Stock Rating
15
Price Target
$73.00
Consensus
Outperform
Upside
30.24%
Analysts
7
Stock Rating
15
Upside
30.24%
Analysts
7
Price Target
$73.00

Catalent Stock Forecast and Price Target

The average price target of $73.00 for Catalent's stock set by seven distinguished analysts in recent weeks would represent a potential upside of approximately 30.24% from the last closing price in February, 2023 if reached by the end of the year. This potential increase is based on a high estimate of $100.00 and a low estimate of $58.00. Even if you are not interested in CTLT stock, it is still imperative to be aware of its competitors.

$73.00

30.24% Upside

Outperform
Outperform

Catalent Fair Value Forecast for 2023 - 2025 - 2030

Catalent's Price has seen impressive growth In the last three years, rising from $55.89 to $118.58 – a growth of 112.15%. According to the 0 analysts polled, in the next year, Catalent's Fair Value will fall by 21.88%, reaching $92.63. By 2030, professionals believe that Catalent's Fair Value will have decreased by 20.23%, falling to $94.59.

2023 Fair Value Forecast
$92.63
2024 Fair Value Forecast
$85.41
2025 Fair Value Forecast
$89.86
2026 Fair Value Forecast
$99.30
2027 Fair Value Forecast
$97.31
2028 Fair Value Forecast
$93.28
2029 Fair Value Forecast
$92.31
2030 Fair Value Forecast
$94.59
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
TMO Stock Forecast Thermo Fisher Scientific Inc Outperform 10
$587.76 $618.99 5.49%
ABT Stock Forecast Abbott Laboratories Outperform 10
$111.79 $120.97 11.82%
A207940 Stock Forecast Samsung Biologics Buy 16
₩808.00k ₩0.00 36.14%
IQV Stock Forecast IQVIA Holdings Buy 16
$237.18 $257.89 9.62%
603259 Stock Forecast WuXi AppTec Buy 18
¥87.57 ¥0.00 56.21%

Catalent Revenue Forecast for 2023 - 2025 - 2030

Catalent's Revenue has seen impressive growth In the last three years, rising from $2.52B to $4.83B – a growth of 91.74%. According to the 0 analysts polled, in the next year, Catalent's Revenue will fall by 19.47%, reaching $3.89B. By 2030, professionals believe that Catalent's Revenue will have decreased by 17.19%, falling to $4.00B.

2023 Rev Forecast
$3.89B
2024 Rev Forecast
$3.69B
2025 Rev Forecast
$3.84B
2026 Rev Forecast
$4.17B
2027 Rev Forecast
$4.08B
2028 Rev Forecast
$3.95B
2029 Rev Forecast
$3.92B
2030 Rev Forecast
$4.00B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
LONN Stock Forecast Lonza Group Ltd Outperform 16
CHF457.90 CHF756.46 71.98%
2269 Stock Forecast WuXi Biologics (Cayman) Buy 14
HK$66.05 HK$0.00 36.50%
DGX Stock Forecast Quest Diagnostics Hold 10
$142.81 $147.77 1.18%

Catalent Dividend per Share Forecast for 2023 - 2025 - 2030

Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
ICLR Stock Forecast ICON Public Outperform 16
$200.45 $0.00 34.45%
VTRS Stock Forecast Viatris Outperform 8
$12.18 $13.70 10.84%
ERF Stock Forecast Eurofins Scientific Hold 18
66.16€ 0.00€ 58.71%

Catalent Free Cash Flow Forecast for 2023 - 2025 - 2030

Catalent's Free Cash Flow has decreased In the last three years, from $30.00M to $-221.00M – a 836.67% drop. Analysts predict that Catalent's Free Cash Flow will increase in the upcoming year, reaching $-324.24M. This would represent an increase of 46.71%. Over the next eight years, experts predict that Catalent's Free Cash Flow will grow at a rate of 12.05%.

2023 FCF Forecast
$-324236466.67
2024 FCF Forecast
$-208505663.83
2025 FCF Forecast
$-235013683.89
2026 FCF Forecast
$-244711915.25
2027 FCF Forecast
$-277552254.27
2028 FCF Forecast
$-252507789.20
2029 FCF Forecast
$-247567053.46
2030 FCF Forecast
$-247641323.57
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
300759 Stock Forecast Pharmaron Beijing Outperform 16
¥74.72 ¥0.00 107.23%
CRL Stock Forecast Charles River Laboratories Int... Outperform 16
$250.35 $268.54 3.85%
500124 Stock Forecast Dr. Reddy's Laboratories Outperform 18
Rp4.27k Rp5.47k 15.97%

Catalent Net Income Forecast for 2023 - 2025 - 2030

In the last three years, Catalent's Net Income has grown, moving from $137.00M to $519.00M – an increase of 278.83%. According to 0 prominent analysts, Catalent's Net Income will fall by 29.17% in the next year, reaching $367.61M. By 2030, professionals believe that Catalent's Net Income will decrease by 16.99%, reaching $430.81M – a concerning trend for the company.

2023 NI Forecast
$0.37B
2024 NI Forecast
$0.36B
2025 NI Forecast
$0.43B
2026 NI Forecast
$0.46B
2027 NI Forecast
$0.43B
2028 NI Forecast
$0.41B
2029 NI Forecast
$0.41B
2030 NI Forecast
$0.43B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
002821 Stock Forecast Asymchem Laboratories (Tianjin... Buy 16
¥166.30 ¥0.00 155.89%
603456 Stock Forecast Zhejiang Jiuzhou Pharmaceutica... Buy 18
¥43.51 ¥0.00 58.19%
PRGO Stock Forecast Perrigo Buy 16
$37.20 $47.75 27.69%

Catalent EBITDA Forecast for 2023 - 2025 - 2030

Catalent's EBITDA has seen growth In the last three years, going from $522.00M to $1.13B – a gain of 115.65% According to 0 major analysts, Catalent's EBITDA will fall by 22.33% in the next year, reaching $874.35M. Professionals believe that By 2030, Catalent's EBITDA will fall to $914.68M– a 18.74% decrease from its current value.

2023 EBITDA Forecast
$0.87B
2024 EBITDA Forecast
$0.82B
2025 EBITDA Forecast
$0.88B
2026 EBITDA Forecast
$0.96B
2027 EBITDA Forecast
$0.93B
2028 EBITDA Forecast
$0.90B
2029 EBITDA Forecast
$0.89B
2030 EBITDA Forecast
$0.91B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
300363 Stock Forecast Porton Pharma Solutions Buy 18
¥51.12 ¥0.00 131.81%
EVT Stock Forecast Evotec Outperform 14
18.92€ 37.33€ 74.42%
SYNH Stock Forecast Syneos Health Outperform 16
$37.93 $90.75 -10.36%

Catalent EBIT Forecast for 2023 - 2025 - 2030

In the last three years, EBIT for Catalent has grown by 157.68%, going from $293.00M to $755.00M. In the next year, 0 analysts estimate that Catalent's EBIT will decrease by 26.23%, reaching $556.94M. According to professional forecasts, in 2030, Catalent's EBIT will decrease by 20.09%, reaching $603.29M.

2023 EBIT Forecast
$0.56B
2024 EBIT Forecast
$0.53B
2025 EBIT Forecast
$0.58B
2026 EBIT Forecast
$0.64B
2027 EBIT Forecast
$0.61B
2028 EBIT Forecast
$0.59B
2029 EBIT Forecast
$0.58B
2030 EBIT Forecast
$0.60B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
EBS Stock Forecast Emergent BioSolutions Outperform 16
$13.97 $44.50 168.43%
CDMO Stock Forecast Avid Bioservices Outperform 12
$16.19 $28.25 72.95%
LH Stock Forecast Laboratory Corp of America Hol... Outperform 11
$251.71 $278.38 9.25%

Catalent EPS Price Prediction Forecast for 2023 - 2025 - 2030

Catalent's EPS has seen impressive growth In the last three years, rising from $1.81 to $3.84 – a growth of 112.15%. According to the 0 analysts polled, in the next year, Catalent's EPS will fall by 21.88%, reaching $3.00. By 2030, professionals believe that Catalent's EPS will have decreased by 20.23%, falling to $3.06.

2023 EPS Forecast
$3.00
2024 EPS Forecast
$2.77
2025 EPS Forecast
$2.91
2026 EPS Forecast
$3.22
2027 EPS Forecast
$3.15
2028 EPS Forecast
$3.02
2029 EPS Forecast
$2.99
2030 EPS Forecast
$3.06